Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: A network meta-analysis
Rheumatology | Dec 16, 2017
Wu D, et al. - This study entails analysis of data from randomized controlled trials assessing the comparative efficacy, safety and tolerability of IL-6, IL-12/23 and IL-17 inhibitors for patients with active PsA. As per the evidence, among all the new biologics targeting IL-6, IL-12/23 and IL-17 pathways, secukinumab may be the safest and most efficacious short-term treatment for peripheral PsA.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
